光学相干断层成像评价植入不同药物洗脱支架后的血管愈合情况

目的应用光学相干断层成像（OCT）比较急性心肌梗死（AMI）患者植入不同药物洗脱支架（DES）后的新生内膜覆盖和支架贴壁情况以评估血管愈合。方法 49例AMI患者植入不同DES后9个月时进行OCT检查。其中20个雷帕霉素药物洗脱支架（SES,Cypher）,12个紫杉醇药物洗脱支架（PES,Taxus）和17个雷帕霉素衍生物药物洗脱支架（ZES,Endeavor）。每隔1mm评估OCT横断面影像每个支架柱的新生内膜覆盖和贴壁情况,同时观察每个支架内的血栓发生情况。结果总计对12378个支架柱进行了分析。SES的新生内膜增生最少,新生内膜厚度：SES（77±60）μm、PES（153±82）μm、ZES（265±130）μm,且新生内膜增生面积百分比最低,SES（10±8）%、PES（19±8）%、ZES（28±9）%,但SES和PES有更多未被新生内膜覆盖的支架柱,SES（15.1±16）%、PES（7.1±10）%、ZES（0.6±1.5）%,且贴壁不良支架柱的发生率也高于ZES,SES（3.8±7.2）%、PES（2.1±4.4）%、ZES（0±0）%,而有完全新生内膜覆盖的支架比例以ZES为高,SES5%、PES33.3%、ZES82.4%。血栓的发生率SES和PES高于ZES,SES34%、PES33%、ZES6%。结论 AMI患者植入不同类型DES后,其支架的新生内膜覆盖程度和贴壁不良的发生率是显著不同的,因此DES的类型可能影响了AMI血栓性病变的血管愈合过程。     

光学相干断层成像技术评价猪冠状动脉佐他莫司洗脱支架术后早期新生内膜覆盖情况

目的:应用光学相干断层成像(OCT)、病理和扫描电镜评价猪冠状动脉佐他莫司洗脱支架(ZES)术后早期(7天、14天、28天)新生内膜覆盖情况。方法:18只中华小型猪随机分为7天组、14天组和28天组,每组6只,每只猪于右冠状动脉置入一枚佐他莫司洗脱支架,3组实验动物分别于术后7天、14天及28天时进行OCT检查,观察支架表面新生内膜覆盖情况,并取支架段冠状动脉进行病理组织学检查及扫描电镜观察。结果:用OCT观察3个时间段支架表面新生内膜情况,7天组为(61.3±37.7)μm,14天组为(132.6±103.3)μm,28天组为(244.3±282.3)μm,3组间差异有统计学意义(P<0.001),新生内膜覆盖率7天组为(53.62±2.49)%,28天组达到(94.88±2.93)%,病理提示7天时新生内膜以炎性细胞、红细胞、血小板为主,28天时以平滑肌细胞、炎性细胞和血管内皮细胞为主。结论:OCT在支架术后7天即能清晰观察到新生内膜覆盖情况,佐他莫司洗脱支架术后28天大多数支架丝被新生内膜覆盖。     

光学相干断层显像评价药物洗脱支架置入后内膜增殖和血栓形成

目的 应用光学干涉断层显像(OCT)技术评价雷帕霉素洗脱支架(SES)置入后3个月和2年后内膜增殖和支架内血栓形成情况.方法 对3个月组进行SES置入后3个月的OCT随访观察,对2年组进行SES置入后2年的随访观察.测量每一个支架支撑杆表面的新生内膜厚度,并评估无内膜覆盖支架支撑杆及支架内血栓形成情况.结果 2年组的内膜厚度显著大于3个月组[(71±93)μm比(29±41)μm,P＜0.01],而2年组中的无内膜覆盖支架支撑杆的比例明显低于3个月组(5%比15%,P＜0.01).2年组与3个月组无内膜覆盖支撑杆患者的比例差异无统计学意义(81%比95%,P＞0.05).两组中均有14%的患者出现无临床症状的支架内血栓形成.结论 SES置入后3个月到2年新生内膜的增生在不断进展,无内膜覆盖支撑杆数明显减少.但是直到支架置入后2年,多数患者体内仍然存在部分无内膜覆盖的支架支撑杆.     

抗CD34抗体优化雷帕霉素洗脱支架疗效的实验研究

目的 评价抗CD34抗体对雷帕霉素洗脱支架早期再内皮化以及远期抗再狭窄的影响.方法 将裸金属支架(BMS)、雷帕霉素洗脱支架(SES)和抗CD34抗体与雷帕霉素洗脱联合支架(ASES)随机置入到22头中华小型猪的冠状动脉内(共置入15枚BMS、17枚SES和16枚ASES).10头中华小型猪在置入支架(共置入6枚BMS、7枚SES和7枚ASES)后2周,另外12头中华小型猪在置入支架(共置入9枚BMS、10枚SES和9枚ASES)后3个月,进行冠状动脉造影及冠状动脉内光学相干断层成像( OCT)检查,并在处死动物后对支架段冠状动脉进行病理组织学检查及扫描电镜观察.结果 (1)支架术后2周,冠状动脉造影、OCT图像及支架段冠状动脉的病理组织学的观察均未发现支架内血栓及小的附壁血栓.对OCT图像的分析显示,ASES新生内膜覆盖率显著高于SES[ (55.56±35.27)％比(41.82±23.28)％,P＜0.05];ASES平均内膜覆盖厚度不但显著高于SES[(89.0±5.0)μm比(32.0±4.9) μm,P＜0.01],而且显著高于BMS[( 89.0±5.0) μ,m比(44.0±7.2)μm,P＜0.01].病理组织学观察及扫描电镜观察显示,ASES和BMS新生内膜覆盖水平及质量均优于SES.(2)支架术后3个月,定量冠状动脉造影显示ASES晚期支架内管腔丢失显著低于BMS [(0.18±0.06)mm比(0.35±0.06)mm,P＜0.05];对OCT图像的分析显示,ASES和SES新生内膜增生百分比均显著低于BMS[ (34.75±2.64)％和(35.63±2.07)％比(48.28±3.25)％,均P＜0.01];组织病理学分析显示,ASES和SES面积再狭窄百分比均显著低于BMS组[(28.65±5.64)％和(29.33±6.07)％比(46.18±8.25)％,均P＜0.05].结论 将抗CD34抗体联合应用到雷帕霉素洗脱支架上能够显著抵消后者在支架术后2周对再内皮化的抑制作用,同时没有削弱雷帕霉素洗脱支架术后3个月的抗再狭窄效能.     

雷帕霉素药物洗脱支架对糖尿病小型猪冠状动脉支架置入后内膜增生的影响

目的:评估雷帕霉素药物洗脱支架(SES)对糖尿病小型猪冠状动脉支架置入后内膜增生的作用.方法:建立链脲菌素诱导的糖尿病小型猪模型(糖尿病组,n=12),随机选取2支冠状动脉置入SES,共计置入24枚支架,术后饲养6个月,与非糖尿病置入SES支架的小型猪模型(对照组,n=12)比较冠状动脉造影、血管内超声及组织切片检查结果.结果:两组动物支架置入冠状动脉分布,术前参照血管直径[糖尿病组:(2.78±0.35)mm,对照组:(2.81±0.29)mm]及术后即刻最小管腔内径[糖尿病组:(2.90±0.42)mm,对照组:(2.89±0.33)mm]均相似(P均>0.05).术后6个月糖尿病组支架内狭窄程度[(35.6±9.2)%和(7.9±3.1)%,P<0.001]、支架内晚期管腔丢失[(0.32±0.09)mm和(0.09±0.04)mm,P<0.001]、新生内膜厚度[血管内超声:(0.35±0.12)mm和(0.11±0.08)mm,P<0.05]及新生内膜面积[血管内超声:(1.29±0.51)mm~2和(0.26±0.11)mm~2,P<0.001;组织切片:(1.24±0.76)mm~2和(0.19±0.08)mm~2,P<0.05]均显著高于对照组.结论:糖尿病小型猪冠状动脉置入SES后内膜增生程度显著高于无糖尿病模型.     

新型生物可降解聚合物雷帕霉素靶向洗脱支架预防支架内狭窄的动物实验研究

目的:评价新型的生物可降解聚合物雷帕霉素靶向洗脱支架—Firehawk在小型猪冠状动脉模型预防支架内狭窄的疗效。方法:将Firehawk支架(Firehawk组,n=10)和采用永久聚合物涂层雷帕霉素洗脱支架Firebird 2(Firebird 2组,n=8)置入健康小型猪冠状动脉。术后4周时测定两组支架血管段的平均内膜厚度、新生内膜面积、面积狭窄百分比等参数,以比较其内膜增生的情况。结果:术后4周,Firehawk组和Firebird 2组平均内膜厚度分别为(0.15±0.10)mm和(0.14±0.06)mm,新生内膜面积分别为(1.12±0.57)mm2和(1.04±0.36)mm2,面积狭窄百分比分别为(24.58±14.85)%和(26.80±10.64)%,差异均无统计学意义(P均>0.05)。两组均无支架内狭窄发生。结论:Firehawk支架可有效抑制支架置入后4周时的内膜增生,预防冠状动脉实验性支架内狭窄,效果与传统的永久聚合物涂层药物洗脱支架相当。长期效果有待进一步观察。     

Mytrolimus药物洗脱支架预防支架内再狭窄的实验研究

目的评价新型聚烯烃类高分子化合物涂层携载雷帕霉素衍生物-Mytrolimus(CCI-779)洗脱支架在小型猪冠状动脉模型预防再狭窄的疗效。方法小型猪冠状动脉分别置入裸支架、单纯聚烯烃类高分子化合物涂层支架和Mytrolimus洗脱支架(160μg/18mm)。术后4周重复冠状动脉造影后处死动物,测定3组支架血管段的损伤指数、冠状动脉横截面积、管腔面积、支架上平均内膜厚度、支架间平均内膜厚度、新生内膜面积、面积再狭窄百分比,并作比较。结果裸支架组(置入支架数n=10)、单纯聚烯烃类高分子化合物涂层支架组(n=10)和Mytrolimus洗脱支架组(n=8)3组冠状动脉大小和血管损伤程度基本相同,术后4周,单纯聚烯烃类高分子化合物涂层组与裸支架比较多项参数差异均无统计学意义。Mytrolimus药物洗脱支架组和裸支架组的支架上内膜厚度分别为(0.18±0.08)mm和(0.33±0.25)mm(P<0.05);支架间内膜厚度分别为(0.14±0.05)mm和(0.28±0.23)mm(P<0.05);新生内膜面积分别为(1.09±0.24)mm2和(2.44±1.59)mm2(P<0.05)。上述多项参数在Mytroliums洗脱支架组均显著少于裸支架组。Mytrolimus组新生内膜面积比裸支架组少了55.33%,且Mytrolimus组无一例再狭窄。结论Mytrolimus洗脱支架在置入小型猪冠状动脉4周时可有效抑制内膜增生、预防冠状动脉实验性支架内再狭窄。     

抗CD34抗体抵消雷帕霉素洗脱支架内皮延迟修复研究

目的:雷帕霉素洗脱支架在降低再狭窄风险的同时,通过抑制血管再内皮化,可能增加支架内血栓发生风险,抗CD34抗体通过特异捕获血液中内皮祖细胞,加速支架术后血管再内皮化。本研究目的是将抗CD34抗体涂敷到雷帕霉素洗脱支架上,通过实验小猪支架术后不同时间造影,随访评价抗CD34抗体对雷帕霉素洗脱支架早期再内皮化的影响。方法:将3种不同类型的支架包括金属裸支架(bare-metal stents,BMS)、雷帕霉素洗脱支架(sirolimous-eluting stents,SES)和抗CD34抗体与雷帕霉素洗脱联合支架(anti-CD34 antibody and sirolimous-eluting combined stents,ASES)随机植入到符合条件的10头中华小型猪冠状动脉内(共植入了6个BMS、7个支架和7个ASES),支架植入术后2 w,进行冠状动脉造影及冠状动脉内光学相干断层成像(optical coherence tomography,OCT)检查;动物处死后,对支架段冠状动脉进行病理组织学检查及扫描电镜观察。结果:1.通过对冠状动脉造影、OCT图像及支架段冠状动脉的病理组织学的观察分析,均未发现支架内血栓及小的附壁血栓。2.在2 w OCT检查图像上,ASES新生内膜覆盖率显著高于SES[(55.56±35.27)%vs.(41.82±23.28)%,P=0.047],ASES平均内膜覆盖厚度不但显著高于SES[(89±5.0)μm vs.(32±4.9)μm,P<0.001]、还高于BMS[(89±5.0)μm vs.(44±7.2)μm,P=0.001]。病理组织学观察及扫描电镜观察也显示,ASES和BMS新生内膜覆盖水平及质量均优于SES。结论:将抗CD34抗体联合应用到雷帕霉素洗脱支架上,能够显著抵消后者在支架术后早期对再内皮化的抑制作用。     

采用光学相干断层成像技术评价海利欧斯雷帕霉素洗脱支架术9个月后内膜覆盖情况

目的 应用光学相干断层成像评价国产雷帕霉素洗脱支架置入后支架内血管新生内膜的生长情况,并能对患者的双重抗血小板药物治疗疗程提供依据.方法 对10例置入海利欧斯药物洗脱支架患者术后常规抗血小板治疗9个月后行冠状动脉血管内光学相干断层成像检查,间隔1 mm测量每个截面中支架小梁的新生内膜覆盖情况.结果 总共测量296 mm长度支架阶段的2 063个支架小梁,支架血管内膜无覆盖率是64.6%,有内膜覆盖的平均内膜厚度是95.70±66.62 μm,平均新生内膜面积的管腔百分比为5.061 8%±5.662 5%.结论 海利欧斯洗脱支架植入9个月后内膜覆盖不良的比例较高,提示对于海利欧斯洗脱支架的随访时间应该更长,双联抗血小板治疗疗程也应该更长.     

采用光学相干断层成像评价无再狭窄药物洗脱支架内膜增生

目的应用冠状动脉血管内光学相干断层成像技术(optical coherence tomography,OCT)评价造影随访无再狭窄的药物洗脱支架(drug eluting stent,DES)内皮增生情况。方法从北京安贞医院2007年9月至2008年9月连续入选DES术后无症状而接受冠状动脉造影复查无明显再狭窄的患者18例,所有患者接受OCT检查,比较不同的DES植入时间、不同DES组之间,每组支架小梁血管内膜增生情况。结果共分析4709个支架小梁,其中被内皮完全覆盖的支架小梁个数4173个(88.6%),被内皮部分覆盖的个数是33个(0.7%),暴露的小梁个数382个(8.1%);贴壁不良的小梁个数121个(2.6%),覆盖支架小梁的内膜的平均厚度是0.099mm,内膜厚度100μm的小梁个数2378个(50.5%);不同药物洗脱支架之间内膜增生厚度、支架小梁内膜覆盖及晚期支架贴壁不良差异有统计学意义;与DES植入时间12个月相比,植入时间12个月血管内膜增生厚度有明显增加趋势(0.1183mm比0.0875mm;P=0.001);支架内膜无覆盖比率分别是:1.7%比6.8%(P0.05);贴壁不良比率是:2.1%比0.5%(P0.001)。结论通过OCT分析16个月左右的药物洗脱支架血管内膜厚度,总的来说90.1%的支架小梁有内膜覆盖,但是仍然有高达9.9%的无内膜覆盖,支架类型、支架置入时间之间内膜覆盖、支架贴壁有一定差异;同时支架植入大于12个月的支架贴壁不良比率高于不足12个月的,提示更晚期的支架贴壁不良情况存在,对于药物洗脱支架的随访时间应该更长,双联抗血小板治疗疗程也许应该更长。     

Difference of neointimal growth patterns in bifurcation lesions among four kinds of drug‐eluting stents

Aim: Neointimal proliferation of bifurcation lesions after implantation of drug‐eluting stents (DES) has not been well evaluated. Thus, we compared neointimal proliferation of bifurcation lesions among four DES using optical coherence tomography (OCT). Methods: 8‐month follow‐up OCT was performed in 68 bifurcation lesions treated by 15 sirolimus‐eluting stents (SES) and 17 paclitaxel‐eluting stents (PES) as first‐generation DES, and by 17 zotarolimus‐eluting stents (ZES) and 19 everolimus‐eluting stents (EES) as second‐generation DES. Cross‐sectional images of the bifurcation lesion using OCT were analyzed every 450 µm. All images were divided into three areas: inner wall of the bifurcation (IB), outer wall of the bifurcation (OB), and ostium of the side branch (SB). We compared the incidence of uncovered struts (IUS) among three areas and the averaged neointimal thickness (NIH) between IB and OB in each stent and also compared these OCT parameters among all DES. Results: There were no significant differences of IUS between IB and OB in second‐generation DES, while in first‐generation DES, IUS of IB and OB showed significant differences. The IUS of SES in both areas was significantly higher than in the other DES (all P < 0.001). PES had a significantly higher IUS in SB than the others (all P < 0.001). NIH of OB was significantly higher than that of IB in PES, ZES, and EES, but in SES the NIH was similar in the two areas. Conclusions: OCT revealed different neointimal growth patterns among SES, PES, ZES, and EES in bifurcation lesions. © 2014 Wiley Periodicals, Inc.     

Comparison of neointimal coverage by optical coherence tomography of a sirolimus-eluting stent versus a bare-metal stent three months after implantation

No detailed data regarding neointimal coverage of bare-metal stents (BMSs) at 3 months after implantation was reported to date. This investigation was designed to evaluate the neointimal coverage of BMSs compared with sirolimus-eluting stents (SESs) using optical coherence tomography. A prospective optical coherence tomographic follow-up examination was performed 3 months after stent implantation for patients who underwent BMS (n = 16) or SES implantation (n = 24). Neointimal hyperplasia (NIH) thickness on each stent strut and percentage of NIH area in each cross section were measured. Malapposition of stent struts to the vessel wall and the existence of in-stent thrombi were also evaluated. There were 5,076 struts of SESs and 2,875 struts of BMSs identified. NIH thickness and percentage of NIH area in the BMS group were higher than in the SES group (351 +/- 248 vs 31 +/- 39 mum; p <0.0001; 45.0 +/- 14% vs 10.0 +/- 4%; p <0.0001, respectively). The frequency of uncovered struts was higher in the SES group than the BMS group (15% vs 0.1%; p <0.0001). Malapposed struts were observed more frequently in the SES group than the BMS group (15% vs 1.1%; p <0.0001). In conclusion, there was no difference in incidence of in-stent thrombus between the 2 groups (14% vs 0%; p = 0.23). The present study showed almost all BMS struts to be well covered at a 3-month follow-up, suggesting that patients receiving BMS stents may not require dual-antiplatelet therapy >3 months after implantation.     

采用光学相干断层成像技术评价国产雷帕霉素洗脱支架术内膜覆盖情况

Objective:Confirming complete neointimal coverage after implantation of drug-eluting stent(DES)is clinically important because incomplete stent coverage is maybe responsible for late thrombosis and sudden cardiac death.Optical coherence tomography(OCT)is a high-resolution(≈10 μm)imaging technique capable of detecting a thin layer of neointimal hyperplasia(NIH)inside DES.Helios stent system(KinheIy Bio-tech Co(Shenzhen).Ltd)is a new generation of sirolimus eluting stents.Methods:Motorized optical coherence t...     

Incomplete neointimal coverage of sirolimus-eluting stents: angioscopic findings.

OBJECTIVES: The goal of this study was to use angioscopy to investigate the amount of neointimal coverage after sirolimus-eluting stent (SES) implantation. BACKGROUND: Sirolimus-eluting stents reduce intimal hyperplasia. METHODS: We used angioscopy to evaluate 37 consecutive stented coronary artery lesions (15 SES and 22 bare-metal stents [BMS]) in 25 patients (18 men, 7 women) at 3 to 6 months after stent implantation. Angioscopic evaluation focused on: 1) neointimal coverage of stent struts, and 2) the existence of thrombi. The degree of neointimal coverage was classified as grade 0 when there was no neointimal coverage (similar to immediately after the implantation); grade 1 when stent struts bulged into the lumen, but were covered and still translucently visible; grade 2 when stent struts were visible but not clearly seen (not translucent); and grade 3 when stent struts were not visible because they were embedded in the neointima. RESULTS: Thrombi were identified in eight stented segments, tended to be more common with SES (p = 0.14), but were not seen on angiography. Three of the 15 SES (20%) had grade 0 neointimal coverage, and only 2 SES (13.3%) had complete coverage (grades 2/3). In contrast, all 22 BMS showed complete intimal coverage (grades 2/3). Thrombi were more common in stents with incomplete neointimal coverage (p = 0.09). CONCLUSIONS: The SES had incomplete neointimal coverage three to six months after implantation, and this was associated with subclinical thrombus formation.     

Evaluation by optical coherence tomography of neointimal coverage of sirolimus-eluting stent three months after implantation

Confirming complete neointimal coverage after implantation of a drug-eluting stent is clinically important because incomplete stent coverage is responsible for late thrombosis and sudden cardiac death. Optical coherence tomography is a high-resolution (approximately 10 microm) imaging technique capable of detecting a thin layer of neointimal hyperplasia (NIH) inside a sirolimus-eluting stent (SES) and stent malapposition. This investigation evaluated stent exposure and malapposition 3 months after SES implantation using optical coherence tomography in a different clinical presentations, such as acute coronary syndrome (ACS) and non-ACS. Motorized optical coherence tomographic pullback (1 mm/s) was performed at 3-month follow-up to examine consecutive implanted 31 SESs in 21 lesions in 21 patients (9 with ACS and 12 with non-ACS). NIH thickness inside each strut and percent NIH area in each cross section were measured. In total, 4,516 struts in 567-mm single-stented segments were analyzed. Overall, NIH thickness and percent NIH area were 29 +/- 41 microm and 10 +/- 4%, respectively. Rates of exposed struts and exposed struts with malapposition were 15% and 6%, respectively. These were more frequent in patients with ACS than in those with non-ACS (18% vs 13%, p <0.0001; 8% vs 5%, p <0.005, respectively). In conclusion, neointimal coverage over a SES at 3-month follow-up is incomplete in ACS and non-ACS. Our study suggests that dual antiplatelet therapy might be continued >3 months after SES implantation.     

可降解聚乳酸涂层西罗莫司洗脱支架在小型猪冠状动脉模型中的实验研究

目的评价新型L605钴铬合金平台可降解聚乳酸共聚物载体西罗莫司药物洗脱支架（bioabsorbable polymeric sirolimus-eluting stent,BPSES）在小型猪冠状动脉抑制新生内膜增殖的有效性和安全性。方法金属裸支架（bare mental stent,BMS）18枚、单纯可降解聚乳酸共聚物涂层支架（bioabsorbable polymer-only stent,BPOS）18枚以及BPSES 18枚被分别随机置入18头小型猪的前降支（18枚）、回旋支（18枚）以及右冠状动脉（18枚）。置入28天和90天,复查冠状动脉造影评价管腔丢失。置入7天、28天以及90天处死部分动物行塑料包埋硬组织切片染色组织形态学分析。结果置入28天及90天,BPSES与BMS相比,显著降低管腔丢失（28天0.54±0.45 mm比1.11±0.45mm,P=0.048;90天0.42±0.34 mm比0.96±0.41 mm,P=0.024）。在损伤积分相似的情况下,置入28天时BPSES较BMS新生内膜面积明显减少（0.90±0.40 mm2比1.88±0.71 mm2,P=0.015）,而在90天时亦叮见此趋势,7天、28天和90天BPSES和BPOS炎症反应及内皮化程度与BMS相似。结论BPSES在置入小型猪冠状动脉28天后,可以安全有效地抑制新生内膜增殖,90天时亦可见此趋势。     

新型钴铬合金可降解涂层西罗莫司洗脱支架在猪冠状动脉过度扩张模型中对新生内膜的影响

目的：评价L-605钴铬合金支架平台、聚丙交酯-乙交酯（PLGA）共聚物载体西罗莫司药物洗脱支架在小型猪冠状动脉过度扩张模型中的安全性和有效性。方法裸金属支架（BMS,15枚）、已上市可降解涂层西罗莫司药物洗脱支架（EXCEL,21枚）和钴铬合金PLGA共聚物载体西罗莫司药物洗脱支架（Co-P-SES,21枚）分组随机置入30头小型猪的前降支（LAD）28枚,回旋支（LCX）13枚,右冠状动脉（RCA）16枚。术后28 d、91 d及182 d复查冠状动脉造影,评价管腔丢失（LL）等指标后处死动物,进行组织形态学及组织病理学分析。结果术后28 d及91 d,各实验组的管腔丢失、新生内膜面积、炎症积分及内皮化积分差异均无统计学意义,但术后28 d Co-P-SES组在扫描电镜下观察内皮化程度优于EXCEL组;术后182 d,Co-P-SES组与EXCEL组在管腔丢失、炎症积分及内皮化积分中差异均无统计学意义,但在内弹力板环绕面积相似的情况下, Co-P-SES组的管腔面积大于EXCEL组[（4.31±0.94）mm2比（2.62±1.17）mm2,P=0.020）],新生内膜面积小于EXCEL组[（1.87±0.53）mm2比（0.84±0.41）mm2,P=0.004）],差异均有统计学意义。结论在小型猪冠状动脉过度扩张模型中,Co-P-SES的安全性与EXCEL类似,在内皮化及减少新生内膜形成方面可能存在一定优势,有必要进一步临床研究以更好地评价其安全性及有效性。     

Preliminary observations using optical coherence tomography to assess neointimal coverage of a metal stent in a porcine model

BackgroundConcerns surrounding late stent thrombosis have prompted the development of novel imaging techniques to assess neointimal coverage. Recent clinical studies have evaluated optical coherence tomography (OCT) to evaluate neointimal coverage, but pathologic correlation in an animal model is lacking. We assessed the hypothesis that OCT could accurately assess early neointimal coverage in a porcine model.MethodsOCT imaging of bare metal stents in each coronary artery was performed at implantation (n=6), Day 4 (n=3), and Day 20 (n=3), and images were evaluated at three cross-sections per stented segment. Neointimal strut coverage was categorized by OCT as covered or uncovered, and neointimal thickness was determined (Day 20). Pathological correlation was obtained using scanning electron microscopy (SEM) to assess strut coverage (Day 4) and histomorphometry to quantify neointimal thickness (Day 20).ResultsAt Day 4, OCT imaging detected 28 (26%) of 109 uncovered struts, and the ratio of uncovered/total strut area by SEM was 31%. All imaging modalities showed complete coverage at Day 20. Mean (±SE) neointimal thickness at Day 20 was 109±6 μm by OCT (n=116 struts) and 93±5 μm by pathology (n=68). Mean neointimal thickness on a segment-by-segment basis determined by OCT correlated with mean histomorphometric analysis (Reviewer 1: r=.74, P=.092 and Reviewer 2: r=0.60, P=.212).ConclusionsDay 4 represents an important time point for the assessment of early neointimal coverage in the porcine model. OCT imaging accurately assesses the extent and thickness of early neointimal coverage with good pathologic correlation. OCT represents a promising imaging modality for the in vivo assessment of neointimal coverage.     

光学相干断层成像评价不同类型药物洗脱支架置入术后的内膜覆盖

目的 应用光学相干断层成像(OCT)对比不同类型药物洗脱支架(DES)置入后的内膜覆盖情况.方法 入选62例在我院置入DES(15.3±5.7)个月后行OCT检查的患者,依据置入支架类型分为Cypher支架组(病例数=26,支架数=57)、Endeavor支架组(病例数=17,支架数=23)和Firebird支架组(病...